Business Context and Reporting Period
This Form 8-K is filed by Hemispherx Biopharma, Inc. (not AIM Immunotech Inc.) on June 3, 2019. The report details a corporate action regarding a reverse stock split approved by the Board of Directors following stockholder approval.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The only quantitative data relates to capital structure adjustments:
- Pre-split Outstanding Shares: Approximately 96,827,062
- Post-split Outstanding Shares: Approximately 2,200,616
- Split Ratio: 1-for-44
Material Changes
The primary material change is the reduction of outstanding common stock through a 1-for-44 reverse stock split. This action will:
- Reduce the share count from approximately 96.8 million to 2.2 million.
- Round up all resulting fractional shares to the next whole share.
- Adjust per-share exercise prices and share counts for outstanding stock options and warrants proportionately.
- Adjust the number of shares issuable under the 2018 Equity Incentive Plan.
- Leave the number of authorized shares unchanged.
Guidance, Outlook, and Risks
Implementation Timeline: The reverse stock split is anticipated to be effected on June 10, 2019, with trading on a split-adjusted basis commencing on June 11, 2019. The filing does not contain forward-looking financial guidance, management commentary on operational performance, or specific risk factors beyond the mechanics of the split.
Investor Verification Checklist
- Verify the effective date of the reverse stock split (June 10, 2019) and the start of adjusted trading (June 11, 2019).
- Confirm the adjusted exercise prices and share quantities for any held stock options or warrants.
- Check the NYSE American trading status for the ticker symbol HEB post-split.
- Review the filed Certificate of Amendment (Exhibit 3(i).1) for legal specifics of the capitalization change.